Trial reportThe Canadian veterinary journal = La revue veterinaire canadienne2013
Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
Trial report in The Canadian veterinary journal = La revue veterinaire canadienne, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Canine Splenic Hemangiosarcoma: Biological Behavior, Clinical Challenges and Therapeutic Limitations.Animals : an open access journal from MDPI · 2026Review
- Primary Hepatic Hemangiosarcoma With Hemoperitoneum in a Dog: Clinical Course and Therapeutic Outcome.Case reports in veterinary medicine · 2026Article
- Clinical features and prognosis of retroperitoneal hemangiosarcoma in dogs with surgical resection with or without adjuvant doxorubicin.The Journal of veterinary medical science · 2023Review
- Efficacy and adverse events of anthracycline and propranolol combination in five dogs with stage 3 hemangiosarcoma.Open veterinary journal · 2023Article
- Histopathological Grading, Clinical Staging and CD 31 Expression of Canine Splenic Hemangiosarcoma.Veterinary sciences · 2023Article
- Hemangiosarcoma in dogs as a potential non-rodent animal model for drug discovery research of angiosarcoma in humans.Frontiers in oncology · 2023Review
- Article
- Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011-2016) and comparison with doxorubicin-based chemotherapy.Journal of veterinary internal medicine · 2021Article
- Retrospective evaluation of thrombocytopenia and tumor stage as prognostic indicators in dogs with splenic hemangiosarcoma.Journal of the American Veterinary Medical Association · 2021Article
- Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study.BMC veterinary research · 2020Article
- Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).The Canadian veterinary journal = La revue veterinaire canadienne · 2018Article
- Article
- Hemangiosarcoma in a Dog: Unusual Presentation and Increased Survival Using a Complementary/Holistic Approach Combined with Metronomic Chemotherapy.Case reports in veterinary medicine · 2018Article
- Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma.Veterinary sciences · 2015Review
- Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.BMC veterinary research · 2015Article
- Primary cranial mediastinal hemangiosarcoma in a young dog.Irish veterinary journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine hemangiosarcoma (HSA) is a highly malignant tumor for which standard chemotherapy has done little to substantially improve survival. Cyclooxygenase-2 (Cox-2) plays a role in the formation, growth, and metastasis of tumors and inhibitors have demonstrated therapeutic benefit with certain canine cancers. In this prospective study, 21 dogs received adjuvant therapy combining the selective Cox-2 inhibitor deracoxib with doxorubicin, following splenectomy for HSA. The combination was well-tolerated with only low-grade gastrointestinal and hematologic toxicities noted. An overall median survival of 150 days (range; 21 to 1506 days) was noted. Although there was no significant difference in survival based upon stage of disease, dogs with stage III HSA (n = 11) had a median survival of 149 days, which appears to be longer than previously reported. Further studies are warranted to evaluate the potential benefit of Cox-2 inhibitors in the treatment of canine HSA.
Indexed as
Identifiers
23997259PMC3573628W2225865610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.